Cardior Pharmaceuticals received the CE mark for its CardiorHealth miR-132 PCR kit.

The kit is designed to measure circulating microRNA-132 (miR-132) levels in the blood of patients receiving the company’s drug candidate CDR132L, an oligonucleotide-based miR-132 inhibitor now being evaluated in a phase 2 study in patients with heart failure and reduced left ventricular ejection fraction after a myocardial infarction.

The company’s goal with this kit is to ensure consistent measurement of miR-132 levels following CDR132L treatment — an indicator of the target engagement and the compound’s mechanism of action, said Cardior.